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Abstract
Purpose A framework for calculation of adherence for oral
hypoglycemic agents (OHAs) based on data from health-
insurance claims is available. Pharmacy dispensing data aid
identification of nonadherent patients in pharmacy practices.
However, use of these data for calculation of OHA adherence
requires additional methodological categories. We examined
the impact of different methodological choices on estimation
of OHA adherence using pharmacy dispensing data.
Methods Four methodological categories were added to the
framework available to be used for adherence calculation with
pharmacy dispensing data. Three adherence measures were
defined to supply pharmacists with significant information
on OHA use of their patients: (i) percentage of days covered
by use periods of dispensed medication (PDC), (ii) mean rate
of adherent patients with a PDC ≥80 % (MRAP80), and (iii)
mean number of nonadherent patients (MNNP80) per phar-
macy with a PDC <80 %. A basic scenario was developed
from 16 methodological categories. Consequences of choices
for different parameters within these categories on the scores
of the three adherence measures were calculated from dispens-
ing data between July 2013 and July 2014.
Results Data were available for 604,500 OHA users in 1737
community pharmacies in the Netherlands. For the basic sce-
nario, mean PDC for OHAwas 88.3%.MRAP80was 80.3%,
which corresponded to an average of 69 nonadherent patients
per pharmacy. Different choices for parameter values resulted
in score variations for PDC of 85.0–91.8 %, for MRAP80 of
75.3–86.1%, and between 49 and 92MNNP80 per pharmacy.
Conclusion Sixteen methodological categories specified cal-
culation of OHA adherence based on pharmacy dispensing
data. Adherence scores expressed as percentages were rela-
tively robust to variation in parameter values, but differed
substantially for the absolute numbers of nonadherent patients
per pharmacy.
Keywords Adherence calculation . Nonadherence .
Pharmacy dispensing data . Oral hypoglycemic agents
Introduction
Nonadherence to prescribed medication has been identified to
be a major source of suboptimal management of several
chronic diseases [1–5]. A recent Cochrane review reported
that prescription-refill records collected routinely are a more
objective method to measure adherence than self-reporting by
patients, and less expensive than Medication Event
Monitoring Systems [6]. Based on prescription-refill records,
adherence can be measured as average medication availability
by the percentage of days covered by drug use periods of
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dispensed medication (PDC) or the mean rate of adherent
patients for a certain threshold, chosen mostly at
PDC ≥ 80 % (MRAP80). For calculation of these measures,
several methodological choices must be made. Dependent on
these choices, a large variation in corresponding adherence
scores has been reported [7–13].
Transparency in calculation of adherence scores is needed to
assess the validity of results and to enable comparisons between
different studies [14–18]. Wilke et al. defined 12 methodolog-
ical categories and analyzed the influence of variation in param-
eter values within these categories on the prevalence of
nonadherence for oral hypoglycemic agents (OHAs) with
claims data from a health-insurance fund in Germany [7].
These categories addressed choices in patient inclusion (e.g.,
based on the diagnosis, a certain number of prescriptions, and
new or prevalent users), duration of the observation period, and
period of drug use. They dealt with periods of medication ces-
sation and switching within drug classes, stockpiling, overuse
and the threshold of minimumPDC to define nonadherence [7].
Wilke et al. showed that some parameters had a stronger effect
on adherence scores than others. In particular, the availability of
information on the prescribed daily doses (PDDs) used to cal-
culate periods of drug use changed PDC by 25 % [7].
Information on the PDD and the number of tablets dispensed
can be used to calculate periods of drug use more accurately
than counting the number of dispensations. Usually, informa-
tion on PDDs is available from clinical prescribing or dispen-
sation records, but is not always present in databases for health-
insurance claims. Another advantage of pharmacy dispensing
data is that they enable pharmacists to identify patients for
additional pharmaceutical care early as those who do not refill
medication for their chronic disease in time. Community phar-
macists have been shown to improve nonadherence to therapies
for chronic disease using their dispensing data [19–23].
However, pharmacy dispensing data have a limitation in that
adherence scores for patients are usually calculated from dis-
pensations within individual pharmacies only and do not allow
following up of patients for dispensations across different phar-
macies (which is possible from health-insurance claims).
Consequently, additional methodological categories are needed
to identify patients with dispensations in several pharmacies
(Bdrop-in^ patients) and those who cease to visit the pharmacy
because of a change of address, hospital admission, or death
(Bwithout any dispensations in a certain time period^). For
OHA adherence, an additional methodological category for
dealing with insulin besides OHA use is also helpful.
According to guidelines, initiation of insulin usually involves
cessation of all but one OHA used previously. Thus, a reduction
in OHA use in combination with insulin initiation could be
assessed incorrectly as Bpatient nonadherence.^ For implemen-
tation of additional pharmaceutical care to nonadherent patients
in pharmacies, information on the absolute number of patients
identified as being nonadherent per pharmacy is also important.
These theoretical considerations gave rise to develop addi-
tional methodological categories to calculate adherence scores
for OHAs using pharmacy dispensing data.
The main objective of the present study was to calculate
OHA adherence based on a methodological framework for
three measures: (i) PDC, (ii) mean percentage of patients with
a PDC ≥80 (MPAP80), and (iii) mean number of nonadherent
patients at a PDC <80 % (MNNP80) per pharmacy. In addi-
tion, the consequences of alternative methodological choices
on the scores of these adherence measures were calculated.
Methods
Ethical approval of the study protocol
Data from pharmacists and patients were coded and
anonymized before analyses. Use of observational data in de-
scriptive retrospective studies in the Netherlands is not con-
sidered as an interventional trial according to Directive
2001/20/EC and Dutch legislation [24]. Therefore, the study
protocol did not need to be submitted to a medical ethic com-
mittee for approval.
Data sources
In the Netherlands, OHAs are available by prescription only.
All dispensations are registered in the computer system of the
pharmacy per patient for health-insurance claims as well as for
automated surveillance of medication use. Dispensing data
from more than 90 % of the 1981 community pharmacies in
the Netherlands are delivered every month to the Foundation
of Pharmaceutical Statistics (SFK) on a routine basis. These
data provide detailed information on the drugs dispensed, in-
cluding the codes from the Anatomic Therapeutic Chemical
(ATC) system of the World Health Organization [25], the pre-
scribed daily dosage (PDD), and the amount dispensed. From
this information, periods of drug use can be calculated by
dividing the amount dispensed by the PDD. Data on patient
information in the SFK consist of an anonymous number from
the computer system of the local pharmacy and information
on the patient’s sex and year of birth.
Data collection
Data were collected from the SFK for community pharmacies
that had provided complete dispensing data from 1 July 2012
to 1 July 2014. This period covered the study period from 1
July 2013 to 1 July 2014. The data history for the year before
the study period was needed to state first OHA dispensings as
those dispensings within the study periodwithout a dispensing
in the year before. From the community pharmacies included,
patients who used at least one OHA (ATC-code A10B) within
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the study period were eligible to be included in adherence
calculations.Medication could be tracked for a specific patient
over time by a unique anonymous patient code within an
individual pharmacy. Pharmacies with shared populations
and using the same anonymous codes for their patients could
label themselves as Bpharmacy clusters^ at SFK. In these spe-
cific cases, dispensations for these patients could be followed
up across pharmacies within a cluster.
Outcome measures
Two adherence measures were calculated. The first was the
PDC and was the average number of days covered by drug use
periods of dispensed medication in relation to all days during
the study period (calculated from the first day of drug use until
the end of this period as a medication possession rate) [7, 26].
The second measure was MRAP80 as the rate of OHA user
with a PDC ≥80 % within all OHA users in the study period.
An additional outcome measure for the potential effort for the
pharmacists to provide additional care for their nonadherent
patients was defined. This is stated as the mean absolute num-
ber of nonadherent patients at a PDC <80 % (MNNP80) per
pharmacy within the pharmacies included.
Methodological categories to measure adherence using
pharmacy dispensing data
Four methodological categories were added to the methodo-
logical framework with 12 categories for data on health-
insurance claims as defined by Wilke et al. [7] as categories
13–16 (Table 1). Three categories were added with regard to
the use of dispensing data per pharmacy for: drop-in patients;
Bactual patients^ (patients with recent dispensations to ensure
that patients continue to visit a particular pharmacy and did
not, for example, move away or die); the possibility to follow-
up patients for their dispensations from several community
pharmacies within pharmacy clusters. A fourth category was
added whether to include OHA users who also used insulin.
A basic scenario was formulated from all 16 categories.
Each methodological category offered a choice of up to three
parameter values. The choices in this scenario made were
aimed to select patients nonadherent to OHA for additional
pharmaceutical care and to prevent false-positive labeling for
nonadherence (Table 1). The resulting basic case included all
OHAs with at least one OHA dispensation during the study
period (categories 1 and 3), as well as new users and those
who stopped OHA use during the study period (categories 2
and 6), regardless of concomitant use of insulin (category 15)
within the study year (category 4). For subjects who used
several OHA classes concomitantly (category 10), PDC was
calculated in three steps: (i) per patient as the medication pos-
session rate for each OHA class, (ii) the arithmetic mean per
patient of the different medication possession rates, and (iii)
average of the arithmetic patient mean (category 7). Different
OHA classes are used concomitantly in treatment of diabetes
mellitus, so concomitant use of OHAs was considered in the
adherence calculation instead of switching between drug clas-
ses (category 7). To prevent false-positive selection for
nonadherence, only those patients that appeared to visit a par-
ticular pharmacy regularly (categories 11, 13, and 14) were
included. Periods of drug use were calculated as PDC by
dividing the number of dispensed OHA tablets by PDD (cat-
egory 5). These periods were adjusted for early refills (cate-
gory 8). To reflect nonadherence rather than overuse, adher-
ence PDC scores were truncated at 100 % (category 9). For
MRAP, a 80 % threshold was chosen, which corresponded to
other OHA studies [25] (category 12). To assess the impact of
these choices in the basic scenario on the three adherence
measures, parameter values could be varied for nine method-
ological categories from our data (categories 2, 3, 7, 8, and
11–15).
Analyses
Amean value was calculated for each adherence measure. The
range of PDC scores for individual patients was shown by 5th
and 95th percentiles. To examine further the validity of our
assumptions, we undertook three subanalyses.
The first subanalysis determined if OHA cessation might
have been due to insulin use (category 2b). For subjects with
OHA use in the first 6 months of the study period but no OHA
use in the final 6 months, it was investigated whether they
used insulin after OHA cessation.
The second subanalysis explored whether users of one
OHA class might have switched to another drug class (e.g.,
due to side effects) instead of using several OHA classes con-
comitantly (category 7). For OHA users in the first 6 months
of the study period who started using another OHA class,
whether they had ceased to use the earlier used OHA class
was tested.
For the third subanalysis, the influence of clustered data
that allowed follow-up of patients for their dispensations from
different pharmacies (category 16) on adherence scores was
assessed. This analysis could be done for pharmacies that had
labeled themselves as pharmacy clusters in our database.
Scores of adherence measures were compared with adherence
scores calculated for individual pharmacies within these
clusters.
Results
For adherence assessments during the study period, data were
available from 1737 of 1981 community pharmacies (88%) in
the Netherlands. For the basic scenario, 604,500 OHA users
were included (Table 2). Mean PDC with OHA use was
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Table 1 Methodological categories to calculate adherence and identify nonadherence from pharmacy dispensing data





Patient selection based on at least one
dispensing of ATCb drug class A10B
within the study period
Number, source of diagnosisc As pharmacy dispensing data lack
information on diagnoses, diseases have
to be estimated by dispensings. As oral
hypoglycemic agents (OHA) are specifi-
cally used for type 2 diabetes mellitus,
dispensing data can be used to select dia-
betes patients.
If information on diagnoses is available, the
source can be used for more valid patient
selection, e.g., specialist diagnosis
2. Patient type as inclusion
criterion
All patients using at least one
dispensing of ATC class A10B
within the study period, based on a
dispensing in the study period or the
3 months prior
a) Only prevalent users are included
in adherence calculation, new
users are excluded
b) Users that stopped with use of
their medication are excluded
c) Only newly treated patients are
included
a) New users are defined as subjects with an
OHA dispensing during the study period
and no dispensing of any OHA drug
during the prior 12 months
b) Stoppers are defined as subjects without a
refill within the last 4 months of the study
period. This excluded moved or ceased
patients. The period of 4 months was
chosen prescriptions generally are
dispensed for 3 months
c) To choose when specific attention is paid
to starting drug use
3. Minimum number of
prescriptions as
inclusion criterion
At least one dispensing during the study
period
At least two or more dispensings in
the study period
A higher number of dispensings could
indicate that the therapy is chronic or that
the patient is a permanent client of a
community pharmacy. However, in
nonadherence calculation, criteria for a
higher number of dispensings induce bias
by excluding patients who are not
adherent after a small number of
dispensings. To define permanent (no
Bdrop-in^) and actual pharmacy clients,
other parameters can be used (see
category 14 and 15)
4. Observation period Annual analysis: July 2013–July 2014 Analysis for several months or
years
In the literature, observational periods of
several months up to 10 years are used
5. Period of drug use Based on drug supply and prescribed
daily doses
Based on a minimum number of
dispensings
Pharmacy dispensing data offer information
on the prescribed daily dose (PDD). Thus
periods of drug use can be calculated for
distinct pharmaceutical formulations such
as oral drugs by dividing the total number
of dispensed drug units by the PDD.
Another, more basic way, for calculating
nonadherence is to consider a patient as
adherent when a specified number of
prescriptions is refilled during the study
period. Alternative methods of defining
drug use periods, like what Wilke et al.
applied, are based on the defined daily
dose (DDD) or guideline recommenda-
tions. These approaches are however less
accurate and useless when the PDD is
available
6. Time interval under
observation
Interval-based from the first dispensing
until the end of the study period
Dispensing-based (denominator:
first until last dispensing,
numerator: dispensed doses at
the first until the one but least
dispensing)
With an interval-based nonadherence
measure, the end of the interval is taken as
a fixed date. This implicates that periods
of drug discontinuation are included in
the adherence measures.
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Table 1 (continued)
Categorya Basic case Related parameters Considerations for pharmacy dispensing
data
In dispensing-based calculation, discontinu-
ation of therapy is not measured. To
monitor treatment adherence of their
patients, pharmacists also have to eluci-
date the reasons for treatment cessation,
e.g., intentional, in agreement with the
prescriber. Thus, a dispensing-based ap-







Concomitant use considered for
different drug classes: estimation of
the percentage of days covered with
medication (PDC) separately calcu-
lated for the different OHA drug
classes in use by one patient as ar-
ithmetic mean of the ATC
group-specific PDCs
Switching considered between drug
classes: estimation of the PDC as
percentage of days covered by
any OHA drug class
When assessing the PDC, it has to be
decided on which ATC class level
coverage of drug use is considered. This
decision implies whether a patient is still
adherent when switching to another drug,
e.g., from metformin from one brand to
another or also when switching from one
OHA drug class to another (e.g., from
metformin to glibenclamide). As in
T2DM therapy, several OHA classes are
used concomitantly, and thus metformin
may rather have to be used concomitantly
with glibenclamide
8. Stockpiling Stockpiling considered No stockpiling considered When accounting for stockpiling, periods of
drug use are adjusted for early refills
9. Dealing with adherence
>100 % on patient level
Truncation to 100 % No truncation to 100 % With truncation, only nonadherence periods
of underuse are considered with no
periods of overuse. For OHA, overuse
does not seem an issue
10. Number of analyzed
medication classes
Adherence measures for all medication
classes for patients with mono- and
multimedication, within OHA
Inclusion of only patients with
monomedication or only analysis
of one drug
If adherence has to be calculated for a
specific drug (class), adherence measures
could be calculated for instance for
metformin only within patients using
metformin only or also additional OHA
drugs. For pharmacists’ interventions, the
whole diabetes medication has to be taken
into account. Thus, focus on one drug is
not useful
11. Absence periods (e.g.,
hospital stay, holiday)
Exclusion of patients with absence
periods
Inclusion of patients with absence
periods
When measuring adherence from the
dispensings from one pharmacy only,
patients might be falsely classified as
nonadherent because of dispensings from
other pharmacies, at hospital or during
vacation. Periods of drug supplies from
elsewhere are clearly visible in dispensing
maps for patients using several chronic
medications as simultaneous gaps in drug
use. Patients with such gaps in their
medication profiles can be excluded from
adherence calculations to warrant the
measures based on valid information
12. Threshold to calculate
the mean rate of
adherence patients
Threshold for nonadherence at an PDC
<80 %
Threshold for nonadherence at PDC
<60 or <90 %
Some drugs are more and others are less
Bforgiving^ for doses missed. According
to drug class characteristics, the
nonadherence threshold should be
accustomed. A threshold of 80 % is most
common
13. BDrop-in^ patients as
exclusion criterion
Exclusion of Bdrop-in^ patients Inclusion of Bdrop-in^ patients BDrop-in^ patients are defined as those with
only one or two dispensings within four
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88.3 % (5th percentile:95th percentile = 44.4 %:100 %) and
on average 80.3 % of OHA users with a PDC ≥80 %
(MRAP80). These data corresponded to a mean number of
69 nonadherent patients (MNNP80) per pharmacy. Variation
of parameter values within the 16 methodological categories
resulted in score changes for all three adherence measures
(Table 2). Mean adherence scores ranged between 85.0 and
91.8 % for the PDC, between 75.3 and 86.1 % for MRAP80,
and between 49 and 92 for the MNNP80 per pharmacy
(Table 2). Adherence rates increased (with a corresponding
decrease in the absolute number of nonadherent patients per
pharmacy) for parameter choices that excluded new users (cat-
egory 2a), excluded gaps for ceased use of OHA (category
2b), or excluded OHA users with less than two dispensations
(category 3). Adherence scores also increased if gaps in the
use of one OHA class were filled with periods of drug use
from another drug class and, hence, switching between OHA
classes was considered instead of concomitant use (category
7). Finally, adherence scores improved if users of insulin be-
sides OHA use were excluded (category 15).
Adherence rates decreased (with a corresponding increase in
the absolute number of nonadherent patients per pharmacy) for
choices of parameter values that did not consider stockpiling
(category 4), included patients with periods of absence (catego-
ry 5) or included drop-in patients (category 13) or included
patients who did receive any drugs recently (category 14).
Table 1 (continued)
Categorya Basic case Related parameters Considerations for pharmacy dispensing
data
consecutive days of any ATC drug class
within 2 years.
Although the fidelity of Dutch patients to
one community pharmacy is high, in
urban or holiday regions, the number of
patients who only once visit a pharmacy
due to circumstances may be
considerable. These would be falsely
classified as nonadherent
14. BActual patients^ as
exclusion criterion
Exclusion of non-actual patients Inclusion of non-actual patients Non-actual patients are subjects without a
dispensing of any ATC drug class within
the four last months at the end of the study
period. As an example, patients who
moved or died might falsely appear as
nonadherent. These patients can be
excluded as those without any dispensing
in a pharmacy
15. Insulin users as
exclusion criterion
Inclusion of subjects using insulin
concomitantly to OHA
Exclusion of subjects using insulin
concomitantly to OHA
T2DM users who cannot sufficiently be
treated with three different OHA drug
classes should receive insulin. They then
may stop with all or some OHA drug
classes. In this case, OHA discontinuation
would be wrongly assumed as
nonadherent. To avoid misclassification,
insulin users could be excluded from
nonadherence calculation. Use of insulin
was defined by at least one dispensing of
drug class A10A during the study period
16. Data source per
pharmacy or pharmacy
cluster
Individual community pharmacy Clustered data from several
community pharmacies
Valid assessment of patients’ adherence
implies that all dispensings to a patient are
taken into account. Using health-care
claims databases, patient dispensings
from several pharmacies are taken into
account. However, when calculating pa-
tient’s adherence by data from one phar-
macy only, dispensings from other phar-
macies might be missed
aMethodological categories 1–12 were derived from Wilke et al. [7] and expanded by 4 categories relevant for OHA nonadherence measurement by
pharmacy dispensing data
b Anatomic Therapeutic Chemical system of the World Health Organization
c Possible parameter values for variation not used here for the calculation of adherence measures are printed in italic
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Variation of theMRAP80 threshold for a stricter boundary of a
mean medication possession rate of ≥90% (MRAP90) or a more
liberal threshold of 60 % (MRAP60) to be regarded as adherent
resulted in changes of MRAP scores to 69.2 % (MRAP90) and
90.8 % (MRAP60) compared with the basic scenario of 80.3 %
(MRAP80) (category 12). This variation corresponded to a mean
absolute number of 107 nonadherent patients (MNNP90) and 31
nonadherent patients (MNNP60) compared with 69 nonadherent
patients per pharmacy (MNNP80).
The first subanalysis to ascertain if OHA cessationmight have
been due to insulin use (category 2b) involved 36,796 subjects
with OHA use in the first 6 months of the study period and no
use of OHAs in the final 6 months. From these 36,796 subjects,
3505 subjects (9.5 %) used insulin after OHA cessation. The
other 33,291 subjects (90.5 %) did not receive insulin dispensa-
tions after OHA cessation. The second subanalysis (validity of
the assumption for concomitant use of OHA classes instead of
switching from one OHA class to another) involved 604,500
OHA users. From these 604,500 OHA users, 1932 subjects
(0.3 %) were considered to be Bswitchers^ due to starting a
newOHAclass after cessation of the previously usedOHAclass.
For the third subanalysis (effect on adherence measures for fol-
lowing up patients for their dispensations across different phar-
macies), 75 clusters were registered in the SFK database with
258 community pharmacies (13 % of all pharmacies) in the
Netherlands, see supplementary information. On average, a clus-
ter comprised 3.4 pharmacies. Following patients across different
pharmacies increased all adherence scores for clustered data
compared with data from individual pharmacies: for the basic
scenario, PDC improved by 1.7 % for clustered data compared
with dispensations within individual pharmacies, MRAP80 im-
proved by 2.8%, and theMNNP per pharmacy decreased by 19.
Discussion
Overall adherence scores calculated by pharmacy dispensing
data were relatively robust to variations in parameters within a
methodological framework for the PDC and percentage of
subjects with a PDC ≥80 % (MRAP80). Compared with a
basic scenario defined by 16 methodological categories, dif-
ferent parameter choices within these categories changed the
PDC by a maximum of 3.3 % andMRAP80 by a maximum of
5.8 %. These ranges were much lower than the nonadherence
ranges of 16–97 % reported by Wilke et al. [7]. This variation
was mainly due to whether or not information availability on
the PDD. As the PDD was available in dispensing data, this
reason for variation in adherence calculation was overcome by
our data. However, numbers of OHA users per pharmacywere
high, so these percentages corresponded with a substantial
change (between 49 and 92) in the mean absolute numbers
of nonadherent patients per pharmacy. The direction of chang-
es in adherence scores from variations in parameter values
were as expected from theoretical considerations. For
Table 2 Influence of variation in parameter values on adherence measures for oral hypoglycemic agents











Basic case 88.3 (44.4; 100.0) NA 80.3 NA 69 604,500
Effects of parameter values variation compared to the basic case choices, mutually exclusive
2a Only prevalent users, new
users of oral hypoglycemic
agents (OHA) are excluded
89.1 (50.9; 100.0) +0.8 81.5 +1.2 55 513,290
2b Users ceasing OHA use excluded 91.1 (58.6; 100.0) +2.8 84.7 +4.4 50 567,704
3 Users with a minimum number
of OHA dispensings <2 excluded
90.3 (55.9; 100.0) +2.0 82.8 +2.5 57 576,293
7 Switching considered between
OHA drug classes
91.8 (49.6; 100.0) +3.5 86.1 +5.8 46 604,500
8 Stockpiling not considered 85.0 (41.9; 100.0) −3.3 75.6 −4.7 85 604,438
11 Subjects with absence periods included 87.9 (42.7; 100.0) −0.4 79.5 −0.8 72 611,702
13 Drop-in patients included 88.1 (43.0; 100.0) −0.2 80.1 −0.2 70 610,444
14 Patients without actual drug use included 85.0 (28.5; 100.0) −3.3 75.3 −5.0 92 649,004
15 Insulin users excluded 88.9 (47.4; 100.0) +0.6 81.6 +1.3 49 465,454
Based on data from 1737 Dutch community pharmacies
a Numbering corresponding to the methodological categories introduced in Table 1
PDC percentage of days covered by medication, MRAP80 mean rate of adherent patients with a PDC ≥80 %, MNNP80 per pharmacy mean number
nonadherent patient at a PDC < 80 % per pharmacy, NA not applicable
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instance, for MRAP, a variation in the threshold to label pa-
tients as Badherent^ from at a PDC of 60, 80, or 90 % had a
considerable influence on the scores of adherence measures.
In the literature, a PDC of 80 % is commonly assumed to be
sufficient to warrant the expected clinical outcomes. For OHA
use, a PDC <80 % has been shown to be associated with an
increased prevalence of hospitalization [26]. However, other
cut-off points may be relevant depending on the specific drug
treatment.
Another source of changes in adherence scores was the pos-
sibility of following patients according to their dispensations
across different pharmacies by clustered data instead of using
data per individual pharmacy. Use of dispensing data within
individual pharmacies is a general limitation of pharmacy data.
At present pooled data of different pharmacies can be used only
in specific settings by pharmacies using the same anonymous
codes for individual patients. If patients are likely to receive their
medication from different pharmacies, the use of pooled data
from pharmacy clusters can provide the individual pharmacists
with more complete information on their patients’ drug use. As
expected, use of clustered data improved the scores of adherence
measures, though changes were moderate for the PDC and
MRAP80, with improvement of ≈3 % for the basic scenario.
However, for the basic scenario, the absolute numbers of patients
identified for nonadherence decreased by on average 19 patients
per pharmacy. This finding implies that, per pharmacy, 1 in 4 of
the patients identified from data of individual pharmacies only
were labeled falsely as being nonadherent due to dispensations
from other pharmacies. It is probable that such pharmacies who
registered as clusters shared their patient populations most with
other community pharmacies and thus suffered most from in-
complete information of their patients’ drug use. Hence, our
findings from this subgroupmight have overestimated the effects
of clustered data for adherence calculation.
Another source of considerable variation shown by Wilke
et al. addressed category 6 for calculations of drug use within
dispensings versus calculations until the fixed end of an inter-
val (e.g., 1 year) [7]. This criterion resulted in changes in
adherence scores by more than 7 %. Adherence calculations
between dispensations per definition exclude periods of drug
discontinuation and so tend to overestimate adherence in clin-
ical practice. As for pharmaceutical care patients who stop
their treatment for a chronic disease also need to be identified,
variation in a parameter value for adherence within dispensa-
tions was not considered as a relevant alternative in our anal-
ysis. Nevertheless, cessation of one or more OHA might be
related to the start of insulin treatment, in which case the
prescriber stopped OHA use and so an observed discontinua-
tion might not reflect nonadherence. As a limitation of our
study, we did not dispose of information on the reason for
drug discontinuation. To assess the potential resulting bias,
our subanalysis showed that only about 10 % of all subjects
with OHA cessation used insulin subsequently. And even this
limited percentage cannot be fully explained by prescriber-
initiated OHA cessation as guidelines advise continuation of
at least one OHA in combination with insulin. Our basic as-
sumption to consider concomitant use rather than switching
between different OHA classes was confirmed by a
subanalysis which showed that only 0.3 % of OHA users in
the first 6 months of the study period switched to another
OHA class.
In conclusion, a framework with 16 methodological cate-
gories was useful to define OHA adherence based on pharma-
cy dispensing data. Adherence scores expressed as percent-
ages were relatively robust to variations in parameter values
but differed substantially in terms of the absolute numbers of
nonadherent patients per pharmacy.
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